Biotechnology — applications, GM crops & gene editing

Biotechnology means using living organisms, cells, enzymes, genes or biological processes to make useful products or solve practical problems. For UPSC, read it as a bridge between biology, agriculture, health, industry, environment and regulation.

• Core definition: modern biotechnology includes recombinant DNA, tissue culture, monoclonal antibodies, fermentation, genomics, synthetic biology and gene editing. Traditional fermentation is biotechnology too, but exam questions usually target modern tools.
• Constitutional basis: Article 21 links biotechnology regulation with life, health, food safety and environmental protection. Article 48A asks the State to protect the environment. Article 51A(g) makes environmental protection a citizen duty. Article 51A(h) supports scientific temper. Article 246 with the Seventh Schedule distributes law-making powers; agriculture is largely State List, but patents, foreign trade, standards, environment and inter-state regulation bring Union law into the field.
• Main legal instruments: Environment Protection Act, 1986; Rules for Manufacture, Use, Import, Export and Storage of Hazardous Microorganisms, Genetically Engineered Organisms or Cells, 1989; Food Safety and Standards Act, 2006; Biological Diversity Act, 2002; Patents Act, 1970; Seeds Act, 1966; Protection of Plant Varieties and Farmers' Rights Act, 2001; Drugs and Cosmetics Act, 1940 for recombinant medicines and vaccines.
• International frame: the Cartagena Protocol on Biosafety, adopted in 2000 and in force from 2003, deals with safe handling, transport and use of living modified organisms from modern biotechnology.
• Exam boundary: biotechnology is not equal to GM crops. UPSC can ask about vaccines, insulin, diagnostics, bioremediation, biofuels, stem cells, forensic DNA profiling, gene therapy, biosensors and industrial enzymes.
• Limitation: law regulates risk, not curiosity. A laboratory method can be scientifically promising yet require approvals before environmental release, food use, clinical use or commercial sale.
• Legal-basis nuance: the Environment Protection Act route matters because biotechnology risk is treated as environmental and health risk, not merely as agricultural extension. That is why a crop trial can require central biosafety scrutiny even though day-to-day agriculture is a State subject.
• Schedules and entries to remember: Union List entries on patents, foreign trade, standards and research institutions interact with State List agriculture entries. This overlap explains why a single GM crop can involve seed law, environmental clearance, food safety, biodiversity access and intellectual property at the same time.
• Contemporary policy frame: India's recent biotechnology policy language emphasises bio-manufacturing, bio-foundries, bio-based chemicals, precision biotherapeutics and climate-resilient agriculture. For Prelims, treat these as applications of the same cell-gene-enzyme toolkit rather than as unrelated schemes.
• Clinical regulator link: a recombinant drug or vaccine is not cleared merely because its gene construct is known. It needs manufacturing quality, pre-clinical evidence where applicable, clinical-trial approval, adverse-event monitoring and batch consistency.
• Environmental law link: if a biotechnology product can affect soil organisms, insects, wild relatives or water systems, environmental governance becomes part of the science question.